Arcturus Therapeutics

(NASDAQ) ARCT

Current Price$8.56

Market Cap$238.75M

Since IPO (2017)-17%

5 Year-77%

1 Year-34%

1 Month+22%

Arcturus Therapeutics Financials at a Glance

Market Cap

$238.75M

Revenue (TTM)

$74.12M

Net Income (TTM)

$65.78M

EPS (TTM)

$-2.39

P/E Ratio

-3.52

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$8.56

Volume

759

Open

$8.37

Price

$8.56

Volume

759

Open

$8.37

Previous Close

$8.40

Daily Range

$8.37 - $8.71

52-Week Range

$5.85 - $24.17

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$8.56

Volume

759

Open

$8.37

Previous Close

$8.40

Daily Range

$8.37 - $8.71

52-Week Range

$5.85 - $24.17

ARCT News

vaccine COVID coronavirus pandemic health

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arcturus Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

111

CEO

Joseph E. Payne

Website

www.arcturusrx.com

Headquarters

San Diego, CA 92121, US

ARCT Financials

Key Financial Metrics (TTM)

Gross Margin

95%

Operating Margin

-1%

Net Income Margin

-89%

Return on Equity

-29%

Return on Capital

-32%

Return on Assets

-24%

Earnings Yield

-28.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$238.75M

Shares Outstanding

28.42M

Volume

759

Avg. Volume

464.69K

Financials (TTM)

Gross Profit

$64.20M

Operating Income

$74.95M

EBITDA

$71.93M

Operating Cash Flow

$74.27M

Capital Expenditure

$230.00K

Free Cash Flow

$74.27M

Cash & ST Invst.

$230.91M

Total Debt

$25.00M

Arcturus Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$3.08M

-85.3%

Gross Profit

$2.40M

-88.6%

Gross Margin

77.86%

N/A

Market Cap

$238.75M

N/A

Market Cap/Employee

$1.37M

N/A

Employees

174

N/A

Net Income

$29.08M

+3.1%

EBITDA

$32.16M

-10.2%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$205.91M

-1.2%

Accounts Receivable

$5.56M

+40.0%

Inventory

$0.00

N/A

Long Term Debt

$20.78M

-16.9%

Short Term Debt

$4.21M

+18.6%

Return on Assets

-24.26%

N/A

Return on Invested Capital

-31.93%

N/A

Free Cash Flow

$16.36M

-5662.2%

Operating Cash Flow

$16.23M

-5613.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ACHVAchieve Life Sciences, Inc.

ACHVAchieve Life Sciences, Inc.$4.30+3.73%

VYGRVoyager Therapeutics, Inc.

VYGRVoyager Therapeutics, Inc.$3.67+0.82%

SGMTSagimet Biosciences Inc.

SGMTSagimet Biosciences Inc.$8.49-1.22%

FHTXFoghorn Therapeutics Inc.

FHTXFoghorn Therapeutics Inc.$4.75-0.21%

IMRXImmuneering Corporation

IMRXImmuneering Corporation$5.32+1.33%

ZURAZura Bio Limited

ZURAZura Bio Limited$4.95-1.20%

HUMAHumacyte, Inc.

HUMAHumacyte, Inc.$0.81-1.61%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$12.46+0.10%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.86+0.02%

ETEnergy Transfer

ETEnergy Transfer$19.76+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$53.08-0.02%

HTZHertz Global

HTZHertz Global$5.60-0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.93-0.02%

VISNVistance Networks

VISNVistance Networks$10.47+0.06%

Questions About ARCT

What is the current price of Arcturus Therapeutics?

Arcturus Therapeutics is trading at $8.56 per share.

What is the 52-week range for Arcturus Therapeutics?

Over the past 52 weeks, Arcturus Therapeutics has traded between $5.85 and $24.17.

How much debt does Arcturus Therapeutics have?

As of the most recent reporting period, Arcturus Therapeutics reported total debt of $25.00M.

How much cash does Arcturus Therapeutics have on hand?

Arcturus Therapeutics reported $230.91M in cash and cash equivalents in its most recent financial results.

What is Arcturus Therapeutics’s dividend yield?

Arcturus Therapeutics does not currently have a dividend yield.

Arcturus Therapeutics

Arcturus Therapeutics Financials at a Glance

ARCT News

Why Shares of Arcturus Therapeutics Dropped on Tuesday

Why Arcturus Therapeutics Stock Is Soaring Today

Why Arcturus Therapeutics Stock Is Skyrocketing Today

Could Arcturus Therapeutics Be the Next Moderna?

Why Arcturus Therapeutics Stock Was Up 16% Thursday

Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?

Why Arcturus Therapeutics Stock Is Soaring Today

Which Late-to-the-Party COVID Vaccine Stocks Could Still Be Winners?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Arcturus Therapeutics

ARCT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Arcturus Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ARCT

What is the current price of Arcturus Therapeutics?

What is the 52-week range for Arcturus Therapeutics?

How much debt does Arcturus Therapeutics have?

How much cash does Arcturus Therapeutics have on hand?

What is Arcturus Therapeutics’s dividend yield?

Premium Investing Services